Lilly could obtain approval for a weight loss pill that would unlock even more growth. Investors should never ignore valuations when picking stocks. The price a stock trades at can drastically ...

Approval for orforglipron would not only generate a lot of bullishness for the healthcare stock, but would also provide Eli Lilly with yet another blockbuster drug, and potentially enable it to ...

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Co. (LLY) and Shopify Inc. (SHOP), as well as a micro-cap stock ImmuCell Corp ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative. The stock is reasonably valued given the growth opportunities in front ...

Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and ...

Learn More » Let's take a closer look at the company's results to see if the stock is a buy. After reducing its guidance last month, Eli Lilly's revenue came pretty much in line with its lowered ...

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Co. (LLY) and Shopify Inc. (SHOP), as well as a micro-cap stock ImmuCell Corp. (ICCC ...

In the past 12 months, the stock has surged by over 18%. In the fourth quarter of 2024, Eli Lilly and Company (NYSE:LLY) experienced a 45% surge in revenue, reaching $13.53 billion, fueled by ...